Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Meta-Analysis of Levofloxacin for Contacts of Multidrug-Resistant Tuberculosis.
Duong T, Brigden J, Simon Schaaf H, Garden F, Marais BJ, Anh Nguyen T, White IR, Gibb DM, Nhung NV, Martinson NA, Fairlie L, Martinez L, Layton C, Benedetti A, Marks GB, Turner RM, Seddon JA, Hesseling AC, Fox GJ. Duong T, et al. Among authors: fairlie l. NEJM Evid. 2024 Dec 18:EVIDoa2400190. doi: 10.1056/EVIDoa2400190. Online ahead of print. NEJM Evid. 2024. PMID: 39693627
Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis.
Hesseling AC, Purchase SE, Martinson NA, Fairlie L, Schaaf HS, Brigden J, Staples S, Gibb DM, Garcia-Prats A, Conradie F, McGowan C, Layton C, Batist E, Demers AM, Nyamathe S, Frigati L, Turner R, Duong T, Seddon JA. Hesseling AC, et al. Among authors: fairlie l. N Engl J Med. 2024 Dec 19;391(24):2315-2326. doi: 10.1056/NEJMoa2314318. N Engl J Med. 2024. PMID: 39693542 Clinical Trial.
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial.
Shinde V, Lombard Koen A, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche LF, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Joseph N, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen Jose A, Foulkes S, Ahmed K, Thombrayil A, Kalonji D, Cloney-Clark S, Zhu M, Bennett C, Albert G, Marcheschi A, Plested JS, Neal S, Chau G, Cho I, Fries L, Glenn GM, Madhi SA; 2019nCoV-501 Study Group. Shinde V, et al. Among authors: fairlie l. Hum Vaccin Immunother. 2024 Dec 31;20(1):2425147. doi: 10.1080/21645515.2024.2425147. Epub 2024 Dec 12. Hum Vaccin Immunother. 2024. PMID: 39666396 Free article. Clinical Trial.
Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.
Zehrung D, Innis BL, Suwantika AA, Ameri M, Biellik R, Birchall JC, Cravioto A, Jarrahian C, Fairlie L, Goodson JL, Kochhar S, Kretsinger K, Morgan C, Mvundura M, Rathi N, Clarke E, Mistilis JJ, Uwamwezi MC, Giersing B, Hasso-Agopsowicz M. Zehrung D, et al. Among authors: fairlie l. Vaccines (Basel). 2024 Nov 6;12(11):1258. doi: 10.3390/vaccines12111258. Vaccines (Basel). 2024. PMID: 39591161 Free PMC article.
Burden of Lassa fever disease in pregnant women and children and options for prevention.
Chaudhary M, Cutland CL, Bonet M, Gentile A, Jones CE, Marshall HS, Stergachis A, Voss G, Darko DM, Sevene E, Hyde T, Fairlie L, Kampmann B, Everett D, Munoz FM. Chaudhary M, et al. Among authors: fairlie l. Vaccine. 2025 Jan 1;43(Pt 1):126479. doi: 10.1016/j.vaccine.2024.126479. Epub 2024 Nov 1. Vaccine. 2025. PMID: 39488189 Free article. Review.
Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial.
Masheto G, Brummel SS, Ziemba L, Shepherd J, Mbengeranwa T, Igawa L, Coletti A, Mukura D, Rossouw L, Theron G, Krotje C, Jean-Philippe P, Chakhtoura N, Cassim H, Mathiba SR, Maena J, Murtaugh W, Fairlie L, Currier J, Hoffman R, Chinula L, Sax PE, Stranix-Chibanda L, Lockman S; IMPAACT 2010/VESTED Study Team and Investigators. Masheto G, et al. Among authors: fairlie l. J Acquir Immune Defic Syndr. 2024 Oct 1;97(2):172-179. doi: 10.1097/QAI.0000000000003478. J Acquir Immune Defic Syndr. 2024. PMID: 39250651 Clinical Trial.
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.
Bishop MD, Korutaro V, Boyce CL, Beck IA, Styrchak SM, Knowles K, Ziemba L, Brummel SS, Coletti A, Jean-Philippe P, Chakhtoura N, Vhembo T, Cassim H, Owor M, Fairlie L, Moyo S, Chinula L, Lockman S, Frenkel LM. Bishop MD, et al. Among authors: fairlie l. J Acquir Immune Defic Syndr. 2024 Aug;96(4):385-392. doi: 10.1097/qai.0000000000003435. J Acquir Immune Defic Syndr. 2024. PMID: 39175843 Clinical Trial.
Acceptability of the Dapivirine Vaginal Ring and Daily Oral Pre-exposure Prophylaxis (PrEP) during Pregnancy in Malawi, South Africa, Uganda, and Zimbabwe.
Young AM, Stoner MCD, Mathebula F, Mohuba R, Baez A, Seyama L, Mutero P, Etima J, Fabiano Z, Fairlie L, Mayo AJ, Balkus JE, Song M, Bunge K, Piper J, Balan IC, van der Straten A, Montgomery ET. Young AM, et al. Among authors: fairlie l. AIDS Behav. 2024 Nov;28(11):3615-3628. doi: 10.1007/s10461-024-04421-z. Epub 2024 Jul 25. AIDS Behav. 2024. PMID: 39052199 Free PMC article.
Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants.
Jacobson DL, Crider KS, DeMarrais P, Brummel S, Zhang M, Pfeiffer CM, Moore CA, McCarthy K, Johnston B, Mohammed T, Vhembo T, Kabugho E, Muzorah GA, Cassim H, Fairlie L, Machado ES, Ngocho JS, Shapiro RL, Serghides L, Chakhtoura N, Chinula L, Lockman S. Jacobson DL, et al. Among authors: fairlie l. J Infect Dis. 2024 Nov 15;230(5):1224-1234. doi: 10.1093/infdis/jiae308. J Infect Dis. 2024. PMID: 38877762 Free PMC article. Clinical Trial.
134 results